Compare Funko Inc (FNKO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Neurocrine Biosciences Inc — how do they compare? Funko Inc trades at $6.53 (market cap $363.97M), while Neurocrine Biosciences Inc trades at $142.79 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is far larger — about 39.5× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Neurocrine Biosciences Inc for 23 Days on average.
| FNKO | NBIX | |
|---|---|---|
Market Cap | $363.97M | $14.36B |
Volume | 1,422,651 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $185.50 |
52-Week Low | $2.81 | $123.10 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $584.62M | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.525, up 3.41% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue declined to $908.21M in 2025, but Q2 2026 results showed 7% sales growth and improved EBITDA margins. The company maintains a low P/S ratio of 0.38 and reduced debt, while analyst consensus is a 'Hold' with a $7.58 price target.
The outlook is cautiously optimistic; valuation appears attractive, but negative net income and volatile cash flows pose risks. Upside depends on sustained EBITDA growth and execution of the 'Make Culture POP' strategy, while competitive pressures and consumer spending trends remain key watchpoints for investors.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
